Search

Your search keyword '"Darzentas, Nikos"' showing total 472 results

Search Constraints

Start Over You searched for: Author "Darzentas, Nikos" Remove constraint Author: "Darzentas, Nikos"
472 results on '"Darzentas, Nikos"'

Search Results

2. Use of immune repertoire sequencing to resolve discordant microscopic and immunochemical findings in a case of T cell-rich large B cell lymphoma in a young dog

3. Topology and expressed repertoire of the Felis catus T cell receptor loci.

4. Composite lymphoma of concurrent T zone lymphoma and large cell B cell lymphoma in a dog

5. EuroClonality-NGS recommendations for evaluation of B cell clonality analysis by next-generation sequencing – a structured approach with the DEPART algorithm

6. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials

12. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders

13. Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis

15. Dominant T-cell Receptor Delta Rearrangements in B-cell Precursor Acute Lymphoblastic Leukemia: Leukemic Markers or Physiological γδ T Repertoire?

16. P601: GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSIS

18. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS

19. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

20. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

23. Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications

24. Supplemental Table 4 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors

25. Supplemental Table 5 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors

26. Supplemental Table 1 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors

27. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

28. Supplemental Table 3 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors

29. Supplemental Table 2 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors

30. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

31. Supplemental Figure 1 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors

32. Data from Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

33. Supplementary Table 4 from Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

34. Supplementary Figure 3 from Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

35. Supplementary Table 1 from Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

36. Supplementary Figure 2 from Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

37. Supplementary Figure 1 from Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

38. Supplementary Table 2 from Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

39. Supplementary Table 3 from Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

40. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

41. The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age

43. IGH Rearrangement Evolution in Adult KMT2A-rearranged B-cell Precursor ALL: Implications for Cell-of-origin and MRD Monitoring

44. Somatic TP53 mutations are pre-leukemic events in acute lymphoblastic leukemia

45. Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)

46. Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

47. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study

48. Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

49. ARResT/Interrogate Immunoprofiling Platform: Concepts, Workflows, and Insights

50. cfDNA-Based NGS IG Analysis in Lymphoma

Catalog

Books, media, physical & digital resources